立昂技術(300603.SZ)擬定增募資不超18.77億元 實控人蔘與認購
格隆匯6月2日丨立昂技術(300603.SZ)披露2021年度向特定對象發行股票並在創業板上市預案。發行對象為包括公司控股股東、實際控制人王剛在內的不超過35名特定對象;發行價格為不低於定價基準日前20個交易日公司股票均價的80%;發行數量不超約1.11億股,其中王剛的鎖定期為18個月,其他發行對象的鎖定期為6個月;募資總額不超約18.77億元,其中王剛以現金方式認購金額不低於5000萬元;募資淨額擬用於立昂雲數據(成都)一號基地一期建設項目、立昂雲數據(成都)一號基地二期建設項目、補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.